Aradigm Corp is a United States-based company. The Company is an emerging specialty pharmaceutical company focused on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases. Its inhaled ciprofloxacin formulations are also product candidates for treatment of patients with cystic fibrosis and non-tuberculous mycobacteria, and for the prevention and treatment of high threat and bioterrorism infections, such as inhaled tularemia, pneumonic plague, melioidosis, Q fever and inhaled anthrax.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	4.89M 4.27M 3.94M 3.64M 6.91M 466M 7.02M 47.09M 18.49M 230M 18.34M 17.94M 789M	P/E 2016	-0.72x	P/E 2017	-9.3x
Enterprise Value	12.8M 11.19M 10.33M 9.54M 18.1M 1.22B 18.4M 123M 48.45M 601M 48.05M 47.01M 2.07B	EV / Sales 2016	73.3x	EV / Sales 2017	7.27x
Free-Float	60.28%	Yield 2016 *	-	Yield 2017	-

20-06-29	Aradigm Corporation Went Out of Business	CI
20-06-12	Modified Combined Liquidation Plan and Discosure Statement Approved for Aradigm Corporation	CI
20-04-27	Revised Disclosure Statement Conditionally Approved for Aradigm Corporation	CI
20-04-08	Combined Liquidation Plan and Disclosure Statement Filed by Aradigm Corporation	CI
20-03-30	Grifols, S.A. completed the acquisition of Assets and Intellectual Property of Lipoquin, Free Ciprofloxacin, Apulmiq from Aradigm Corporation (OTCPK:ARDM.Q).	CI
20-03-30	Motion for Asset Sale Approved for Aradigm Corporation	CI
20-03-09	Bidding Procedure Approved for Aradigm Corporation	CI
20-02-20	Motion for Asset Sale Filed by Aradigm Corporation	CI
20-02-20	Grifols, S.A. entered into an asset purchase agreement to acquire Assets and Intellectual Property of Lipoquin, Free Ciprofloxacin, Apulmiq from Aradigm Corporation (OTCPK:ARDM.Q) for $6.3 million.	CI
19-11-05	Second Motion for Exclusivity Period Extension Approved For Aradigm Corporation	CI
19-10-30	Aradigm Corporation Announces Withdrawal of European Marketing Authorization Application for Linhaliq	CI
19-10-21	Aradigm Corporation Receives Feedback Following an Oral Explanation with the European Medicines Agency	CI
19-07-19	Motion for Exclusivity Period Extension Approved For Aradigm Corporation	CI

20-06-15	ARADIGM CORP : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
20-06-04	ARADIGM CORP : Other Events (form 8-K)	AQ
20-04-30	ARADIGM CORP : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
20-04-13	ARADIGM CORP : Other Events (form 8-K)	AQ
20-04-06	Aradigm : Announces Sale of Assets to Grifols, S.A.	AQ

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ARADIGM CORPORATION	+36.88%	+25.50%	-	-	702K
LONZA GROUP AG	+0.58%	+2.06%	+3.90%	+9.78%	50.73B
REVOLUTION MEDICINES, INC.	-2.22%	-1.25%	+391.53%	+593.69%	39.73B
IQVIA HOLDINGS INC.	-0.54%	+0.39%	+27.67%	-5.10%	34.69B
BEONE MEDICINES AG	-1.36%	+0.35%	+19.34%	+55.53%	33.21B
CELLTRION, INC.	+1.21%	-4.58%	+3.00%	+31.73%	26.76B
ASCENDIS PHARMA A/S	-1.81%	-1.48%	-	-	16.8B
MEDPACE HOLDINGS, INC.	+0.51%	-3.47%	+66.38%	+122.57%	15.37B
EUROFINS SCIENTIFIC SE	+0.23%	-0.58%	+13.80%	+16.17%	13.78B
ICON PUBLIC LIMITED COMPANY	-0.62%	-3.09%	+11.43%	-31.02%	12.85B
Average	+3.29%	-0.83%	+67.13%	+99.17%	27.1B
Weighted average by Cap.	-0.48%	-0.23%	+82.75%	+124.64%

	2016	2017
Net sales	195K 171K 157K 145K 276K 18.6M 280K 1.88M 738K 9.16M 732K 716K 31.5M	14.46M 12.65M 11.67M 10.78M 20.45M 1.38B 20.8M 139M 54.76M 680M 54.31M 53.13M 2.34B
Net income	-32.94M -28.81M -26.57M -24.54M -46.57M -3.14B -47.35M -318M -125M -1.55B -124M -121M -5.32B	-10.7M -9.36M -8.64M -7.98M -15.14M -1.02B -15.39M -103M -40.52M -503M -40.19M -39.32M -1.73B
Net Debt	-9.37M -8.2M -7.56M -6.98M -13.25M -894M -13.47M -90.34M -35.48M -440M -35.19M -34.42M -1.51B	7.91M 6.92M 6.38M 5.9M 11.19M 755M 11.38M 76.28M 29.96M 372M 29.71M 29.06M 1.28B

Aradigm Corporation Stock Nasdaq

Stocks

US0385054004

Biotechnology & Medical Research

Valuation: Aradigm Corporation

Latest news : Aradigm Corporation

Press Releases: Aradigm Corporation

Quotes and Performance

Other Biotechnology & Medical Research

Financials

Company Profile